A5063193415- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Gastrointestinal Tumor Research and Treatment
- Colorectal and Anal Carcinomas
- Esophageal and GI Pathology
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Vascular Tumors and Angiosarcomas
- Bone Tumor Diagnosis and Treatments
- Musculoskeletal synovial abnormalities and treatments
- Cardiac tumors and thrombi
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Surgical Treatments
- Multiple and Secondary Primary Cancers
- Neuroblastoma Research and Treatments
- Soft tissue tumor case studies
- Hepatocellular Carcinoma Treatment and Prognosis
Dana-Farber Cancer Institute
2013-2025
McGill University
2014-2024
McGill University Health Centre
2015-2024
Harvard University
2002-2024
Royal Victoria Hospital
2023-2024
Royal Victoria Regional Health Centre
2023-2024
Brigham and Women's Hospital
2002-2024
Dana-Farber Brigham Cancer Center
2024
Hospital Universitario de La Princesa
2019
Centre Léon Bérard
2016-2017
Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance toxicities often limit benefits systemic chemotherapy used to treat metastatic sarcomas. This large randomized placebo-controlled phase III trial evaluated the mTOR inhibitor ridaforolimus assess maintenance disease control advanced sarcomas.Patients with soft tissue or bone who achieved objective response stable prior were randomly assigned receive 40 mg placebo once per day...
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
Purpose Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding generation toxic metabolites. The PICASSO III trial compared doxorubicin plus palifosfamide with placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma. Patients Methods were randomly assigned 1:1 to receive 75 mg/m2 intravenously day 1 150 mg/m2/d days 3 or once every 21 up six cycles. primary end point was progression-free...
Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue without approved treatments. Download a PDF of the Research Summary. We conducted phase 3, international, double-blind, randomized, placebo-controlled trial nirogacestat in adults with progressing desmoid according to Response Evaluation Criteria Solid Tumors, version 1.1. Patients were assigned 1:1 ratio receive oral γ-secretase inhibitor (150 mg) or placebo twice daily. The primary end point was progression-free...
Purpose A phase III study comparing eribulin with dacarbazine in patients advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement overall survival (OS) for the arm, manageable toxicity profile. We now report histology-specific subgroup analysis of efficacy and safety compared LPS, an independently randomized stratified this trial. Methods Patients ≥ 18 years metastatic dedifferentiated, myxoid/round cell, pleomorphic LPS incurable by surgery radiotherapy were included....
The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in a variety of solid tumours, including gastrointestinal (GI) malignancies. Agents targeting the EGFR-mediated signalling pathway are increasingly part therapeutic armamentarium for treatment advanced lung, head-and-neck, and colorectal carcinoma. EGFR inhibitors (EGFRIS) approved Canada include tyrosine kinase erlotinib gefitinib (in selected cases), monoclonal antibodies (mAbs) panitumumab cetuximab....
LBA294 Background: AGOC has limited options after second-line therapy. Regorafenib (Rego), an oral multi-targeted tyrosine kinase inhibitor (TKI) targeting angiogenic, stromal and oncogenic receptor TKs, prolonged progression free survival (PFS) versus placebo (PBO) across all regions/subgroups in the INTEGRATE phase 2 randomised trial (JCO 2016 43(23):2728-2735). IIa was designed to examine if Rego improves overall (OS). Methods: Double-blind placebo-controlled 3 comparing + best supportive...
Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed selinexor. We evaluated the clinical benefit selinexor previously treated DD-LPS whose sarcoma progressed on approved agents.
Abstract Background Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, oncogenic receptor kinases. 160 mg daily prolonged progression free survival compared to placebo (INTEGRATE, phase 2). 80 in combination with nivolumab 3 mg/kg showed promising objective response rates (REGONIVO)....
There is a growing appreciation for radio-sensitiser use in multi-modal cancer treatment models. Squamous cell anal carcinoma (SCAC) rare gastrointestinal tumour traditionally treated with concurrent chemotherapy and radiation. Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, has demonstrated significant efficacy when combined radiation squamous of the head neck (SccH&N). We wanted to assess EGFR Kirsten-ras (K-ras) status SCAC see whether it compares SccH&N.Over 90...
Abstract Purpose: Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony-stimulating factor 1 (CSF1) gene and overexpression CSF1 ligand. Surgery standard care for most patients, but there are limited treatment options patients with TGCT not amenable to surgery. This study evaluates vimseltinib, an investigational, oral, switch-control tyrosine kinase inhibitor designed selectively potently inhibit receptor. Patients Methods:...